Tag: Akers Biosciences

Akers Biosciences revenues, gross profit up 10%, overhead lowered 10%
August 15, 2017 Off

Akers Biosciences revenues, gross profit up 10%, overhead lowered 10%

By Dino Mustafić

Akers Biosciences has announced the results for the first half 2017 in which it posted gross profit to be up 10% to $1,342,160, compared to the same period previous year, $1,217,634. As the total revenues moved up 10% for first 6 months of 2017 which were $1,865,112, compared to the 2016’s first half of $1,694,510, Akers Biosciences’s loss before income tax was reduced by 20% to $2,051,918, from first half in 2016, $2,517,861.

Akers Biosciences to market Heparin PF4 rapid test in Puerto Rico
April 10, 2017 Off

Akers Biosciences to market Heparin PF4 rapid test in Puerto Rico

By Dino Mustafić

Akers Biosciences, a developer of rapid health information technologies, has begun marketing its rapid test for heparin-induced thrombocytopenia (“HIT”) to the large number of hospital facilities in Puerto Rico as an extension of the company’s strategy to accelerate U.S. sales of its flagship product.